155 related articles for article (PubMed ID: 9481720)
1. Iron absorption in erythropoietin-treated haemodialysis patients: effects of iron availability, inflammation and aluminium.
Kooistra MP; Niemantsverdriet EC; van Es A; Mol-Beermann NM; Struyvenberg A; Marx JJ
Nephrol Dial Transplant; 1998 Jan; 13(1):82-8. PubMed ID: 9481720
[TBL] [Abstract][Full Text] [Related]
2. The absorption of iron is disturbed in recombinant human erythropoietin-treated peritoneal dialysis patients.
Kooistra MP; Marx JJ
Nephrol Dial Transplant; 1998 Oct; 13(10):2578-82. PubMed ID: 9794563
[TBL] [Abstract][Full Text] [Related]
3. Hepatic computed tomography for monitoring the iron status of haemodialysis patients with haemosiderosis treated with recombinant human erythropoietin.
De Marchi S; Cecchin E
Clin Sci (Lond); 1991 Jul; 81(1):113-21. PubMed ID: 1649718
[TBL] [Abstract][Full Text] [Related]
4. Aluminium interference in the treatment of haemodialysis patients with recombinant human erythropoietin.
Casati S; Castelnovo C; Campise M; Ponticelli C
Nephrol Dial Transplant; 1990; 5(6):441-3. PubMed ID: 2122321
[TBL] [Abstract][Full Text] [Related]
5. Low-dose continuous iron therapy leads to a positive iron balance and decreased serum transferrin levels in chronic haemodialysis patients.
Canavese C; Bergamo D; Ciccone G; Burdese M; Maddalena E; Barbieri S; Thea A; Fop F
Nephrol Dial Transplant; 2004 Jun; 19(6):1564-70. PubMed ID: 15004263
[TBL] [Abstract][Full Text] [Related]
6. Regulation of iron absorption in iron loaded subjects with end stage renal disease: effects of treatment with recombinant human erythropoietin and reduction of iron stores.
Hughes RT; Smith T; Hesp R; Hulme B; Dukes DC; Bending MB; Pearson J; Raja KB; Cotes PM; Pippard MJ
Br J Haematol; 1992 Oct; 82(2):445-54. PubMed ID: 1419827
[TBL] [Abstract][Full Text] [Related]
7. Recombinant human erythropoietin resistance in iron-replete hemodialysis patients: role of aluminum toxicity.
Tarng DC; Huang TP
Am J Nephrol; 1998; 18(1):1-8. PubMed ID: 9481432
[TBL] [Abstract][Full Text] [Related]
8. Percentage of hypochromic red blood cells as predictor of erythropoietic and iron response after i.v. iron supplementation in maintenance haemodialysis patients.
Braun J; Lindner K; Schreiber M; Heidler RA; Hörl WH
Nephrol Dial Transplant; 1997 Jun; 12(6):1173-81. PubMed ID: 9198047
[TBL] [Abstract][Full Text] [Related]
9. Erythropoietin treatment in haemodialysis patients with iron overload.
el-Reshaid K; Johny KV; Hakim A; Kamel H; Sebeta A; Hourani H; Kanyike FB
Acta Haematol; 1994; 91(3):130-5. PubMed ID: 8091934
[TBL] [Abstract][Full Text] [Related]
10. The role of aluminium and parathyroid hormone in erythropoietin resistance in haemodialysis patients.
Muirhead N; Hodsman AB; Hollomby DJ; Cordy PE
Nephrol Dial Transplant; 1991; 6(5):342-5. PubMed ID: 1870750
[TBL] [Abstract][Full Text] [Related]
11. Reduction in erythropoietin doses by the use of chronic intravenous iron supplementation in iron-replete hemodialysis patients.
Chang CH; Chang CC; Chiang SS
Clin Nephrol; 2002 Feb; 57(2):136-41. PubMed ID: 11863124
[TBL] [Abstract][Full Text] [Related]
12. Experience with zinc protoporphyrin as a marker of endogenous iron availability in chronic haemodialysis patients.
Baldus M; Salopek S; Möller M; Schliesser J; Klooker P; Reddig J; Gansert U; Brass H
Nephrol Dial Transplant; 1996 Mar; 11(3):486-91. PubMed ID: 8710158
[TBL] [Abstract][Full Text] [Related]
13. Gastrointestinal aluminium absorption: is it modulated by the iron-absorptive mechanism?
Cannata JB; Suarez Suarez C; Cuesta V; Rodriguez Roza R; Allende MT; Herrera J; Perez Llanderal J
Proc Eur Dial Transplant Assoc Eur Ren Assoc; 1985; 21():354-9. PubMed ID: 3991522
[TBL] [Abstract][Full Text] [Related]
14. Aluminium overload and response to recombinant human erythropoietin in patients under chronic haemodialysis.
Alfurayh O; Sobh M; Barri Y; Qunibi W; Taher S
Nephrol Dial Transplant; 1992; 7(9):939-43. PubMed ID: 1328942
[TBL] [Abstract][Full Text] [Related]
15. Importance of iron supply for erythropoietin therapy.
Sunder-Plassmann G; Hörl WH
Nephrol Dial Transplant; 1995 Nov; 10(11):2070-6. PubMed ID: 8643170
[TBL] [Abstract][Full Text] [Related]
16. Mathematical approach for estimating iron needs in hemodialysis patients on erythropoietin therapy.
Tarng DC; Huang TP; Chen TW
Am J Nephrol; 1997; 17(2):158-64. PubMed ID: 9096447
[TBL] [Abstract][Full Text] [Related]
17. [Role of iron deficiency in erythropoietin sensitivity in dialysis patients with elevated C-reactive protein].
Martone M; Zanchi R; Panzetta G
G Ital Nefrol; 2003; 20(1):31-7. PubMed ID: 12647284
[TBL] [Abstract][Full Text] [Related]
18. Direct effect of deferoxamine on hemoglobin synthesis in patients on hemodialysis treated with recombinant human erythropoietin.
Romero R; Novoa D; Otero S; Alonso MC; Alonso R; Arcocha V; Arza D; Lens XM; Sanchez-Guisande D
Nephron; 1993; 63(2):164-7. PubMed ID: 8450906
[TBL] [Abstract][Full Text] [Related]
19. Iron availability is transiently improved by intravenous iron medication in patients on chronic hemodialysis.
Rosenlöf K; Kivivuori SM; Grönhagen-Riska C; Teppo AM; Slimes MA
Clin Nephrol; 1995 Apr; 43(4):249-55. PubMed ID: 7606879
[TBL] [Abstract][Full Text] [Related]
20. A parallel, comparative study of intravenous iron versus intravenous ascorbic acid for erythropoietin-hyporesponsive anaemia in haemodialysis patients with iron overload.
Tarng DC; Huang TP
Nephrol Dial Transplant; 1998 Nov; 13(11):2867-72. PubMed ID: 9829492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
